$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Can't I stop taking baricitinib once I start taking it? Long-term use requirements and discontinuation precautions
2026-02-01 22:25:32
Check Details
Is ruxolitinib cream effective in treating eczema? How it compares to other eczema treatments
2026-02-01 22:25:32
Check Details
Will upadatinib develop wildly after discontinuation? Is there a risk of recurrence or worsening of symptoms after discontinuing medication?
2026-02-01 22:25:32
Check Details
Pitobrutinib/pitobrutinib receives positive CHMP review for R/R CLL following use of covalent BTK inhibitor
2026-02-01 22:25:32
Check Details
Talazoparib/talazopanib combined with enzalutamide as first-line treatment for mCRPC improves OS
2026-02-01 22:25:32
Check Details
What are the side effects of Crizotinib/Xalkori? How to respond scientifically
2026-02-01 22:25:32
Check Details
Serpretinib/serpatinib demonstrates durable response in RET fusion-positive non-small cell lung cancer
2026-02-01 22:25:32
Check Details
We all know the efficacy and functions of ensidipine, and scientific medication is guaranteed!
2026-02-01 22:25:32
Check Details
Detailed explanation of the medical insurance reimbursement policy for avatrombopag/Sucoxin
2026-02-01 22:25:32
Check Details
Is giritinib covered by medical insurance? Latest updates on medical insurance reimbursement policies
2026-02-01 22:25:32
Check Details
Is midostaurin covered by medical insurance? Latest reimbursement policies and patient benefits
2026-02-01 22:25:32
Check Details
Detailed instructions for cabergoline and a comprehensive medication guide!
2026-02-01 22:25:32
Check Details
1
2
...
1470
1471
1472
1473
1474
1475
1476
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
4
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Revumenib: Key Considerations Before and During Treatment
7
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
8
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
9
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
10
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
11
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
12
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits